Reading BSX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BSX free→Reading BSX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BSX free→
NYSEHealth CareMedical DevicesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality is mixed, and risk is elevated, while the sector backdrop is a headwind. Compared with sector peers, BSX is above typical. Peer multiples imply a price about 36% above where it trades (it looks cheap on this basis); the read is cheap, quality intact. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $46.92. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $47 BSX trades at 15× p/e, below its 23× p/e peer median. Our $72 fair value sits above the price; high confidence. Analysts: $55–$109. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 35% below a flat-multiple fair value, below our forecast of about 25%. This describes what's priced in, not a forecast of the move.
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.22x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to Fed net liquidity, real (inflation-adjusted) rates, the US dollar, long-term interest rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.83 → $0.83 (-0.4% / 30d). 1 raised, 8 cut, 24 covering analysts.
0 upgrades, 2 downgrades / 30d, 11 maintained. 87% of analysts rate Buy.
11 PT revisions / 30d. Avg target 40.1% above current price.
2 positive, 0 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$123.
How much price usually moves either way.
On a bad day, this stock has moved -$272.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,676.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Finishing the buyback may show confidence in the company's finances. It could help share prices.
Confirms:Final settlement of the ASR is completed by June 30, 2026.
Disproves:The ASR is not done by the expected date or changes a lot.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
Advances: Expand cardiovascular segment
New clearance supports expansion in cardiovascular segment.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. Investment Agreement with MiRus LLC On May 18, 2026, Boston Scientific Corporation (the “ Company ”) issued a press release announcing that the Company has entered into an investment agreement (the “ Investment Agreement ”) with MiRus LLC (“ MiRus ”), a privately held company developing and commercializing proprietary novel biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the Siegel transcatheter aortic valve…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$55.00 – $109.00 (median $77.00) · 27 analysts · as of 2026-06-12
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
BSX Boston Scientific | Above typical Show detailsSector percentile: 96 of 100 | inexpensive | elevated |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 94 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
21 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on increasing net sales through strategic initiatives and market expansion.
Enhance the cardiovascular segment through product innovation and market penetration.
Implement an accelerated share repurchase program to enhance shareholder value.
Improve operational efficiency through cost management and process optimization.
Why it matters: Earnings results will show if Boston Scientific meets its growth targets and can sustain momentum.
Confirms one read:Q2 2026 earnings report shows net sales growth above 7.5% year over year.
Confirms the other:Q2 2026 earnings report shows net sales growth below 5.5% year over year.
Why it matters: The trial results will show if the SIEGEL TAVR valve is safe and effective. This could boost Boston Scientific's cardiovascular segment.
Confirms:The STAR trial shows safe and effective results in patients.
Disproves:Negative trial results or delays in reporting the STAR trial outcomes.
Advances: Expand cardiovascular segment
New clearance supports expansion in cardiovascular segment.
Other Events. Accelerated Share Repurchase Program On May 18, 2026, Boston Scientific Corporation (the “ Company ”) issued a press release announcing that the Company has entered into an accelerated share repurchase (“ ASR ”) agreement with JPMorgan Chase Bank, National Association for $2 billion (the “ Repurchase Price ”) of its common stock, as part of its previously announced $5 billion share repurchase authorization. Under the terms of the ASR, the Company will pay the repurchase price an…
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Entry into a Material Definitive Agreement. Revolving Credit Agreement On February 26, 2026, Boston Scientific Corporation (the “ Company ”) entered into a $3.000 billion revolving credit agreement (the “ 2026 Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. The Company may borrow from time to time up to $3,000,000,000 in revolving credit loans under the 2026 Revolving C…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 18, 2026 the Board of Directors (the “ Board ”) of Boston Scientific Corporation (the “ Company ”), upon the recommendation of the Nominating and Governance Committee of the Board, increased the number of directors comprising the Board from ten to twelve, and appointed each of Catherine R. Smith and Christophe P. Weber to be a director…